Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance ... - Morningstar

Bambusa Therapeutics Inc. secures $15 million in Series Seed funding to develop bispecific antibodies for immunology and inflammation disorders, aiming to advance its pipeline to Phase I clinical studies.